April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Tempol Improves Retinal Blood Flow in the Diabetic Mouse
Author Affiliations & Notes
  • A. S. Yadav
    Dept. of Molecular & Cellular Physiology, LSU Health Sciences Center-Shreveport, Shreveport, Louisiana
  • Footnotes
    Commercial Relationships  A.S. Yadav, None.
  • Footnotes
    Support  Supported by NIH EY017599 (NRH).
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5030. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. S. Yadav; Tempol Improves Retinal Blood Flow in the Diabetic Mouse. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5030.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The aim of these experiments was to explore the role of superoxide in the early decrease of retinal blood flow in diabetic mice.

Methods: : Diabetes was induced by streptozotocin, then 1 week later the C57BL6 mice were administered drinking water with (N=5) or without (N=6) the superoxide dismutase mimetic tempol (1 mM concentration) for the following 3 weeks. Non-diabetic age-matched mice (N=4) were included as controls. For each mouse, measurements of retinal vascular diameters and red blood cell (RBC) velocities were obtained via intravital microscopy for 3-5 feed arterioles (and venules) extending out of (and into) the optic disk, and the average blood flow in these vessels was calculated.

Results: : Arteriolar diameters (given in microns) averaged 57±3 (±SE) in controls, 53±1 in the untreated diabetics, and 60±3 in the tempol-treated diabetics. Venular diameters in these respective groups averaged 69±9, 60±6, and 61±5 microns. These differences did not quite reach statistical significance (p=0.14 for arterioles; p=0.10 for venules); however, statistical differences between groups were present for RBC velocities and blood flow rates. Average arteriolar velocities were significantly decreased in the untreated diabetics (68±6% of controls; p<0.01), but not in the tempol-treated diabetics (103±8% of controls). Similarly, venular velocities averaged 65±6% of controls (p<0.05) in untreated diabetics compared to 96±6% of controls with tempol. Finally, average vessel blood flow (arteriole and venules combined) decreased in the untreated diabetics to 55±6% of controls (p<0.01) compared to 93±11% of controls with tempol.

Conclusions: : Administration of tempol in drinking water for the final 3 weeks of a 4-week streptozotocin protocol is able to attenuate the decrease in blood flow induced by diabetes, suggesting a possible role for superoxide.

Keywords: blood supply • diabetic retinopathy • antioxidants 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×